vTv Therapeutics Inc. (NASDAQ:VTVT) Short Interest Up 78.6% in January

vTv Therapeutics Inc. (NASDAQ:VTVTGet Free Report) was the target of a significant growth in short interest in January. As of January 31st, there was short interest totalling 70,900 shares, a growth of 78.6% from the January 15th total of 39,700 shares. Approximately 10.7% of the company’s stock are short sold. Based on an average trading volume of 31,600 shares, the short-interest ratio is currently 2.2 days.

vTv Therapeutics Price Performance

vTv Therapeutics stock traded up $0.06 during midday trading on Monday, reaching $10.46. 3,186 shares of the company traded hands, compared to its average volume of 25,134. The firm has a market capitalization of $27.30 million, a price-to-earnings ratio of -0.97 and a beta of 0.23. The business has a 50 day moving average of $9.47 and a two-hundred day moving average of $15.79. vTv Therapeutics has a 12 month low of $7.38 and a 12 month high of $39.60.

vTv Therapeutics (NASDAQ:VTVTGet Free Report) last issued its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($3.20) earnings per share for the quarter.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Pathstone Family Office LLC purchased a new stake in shares of vTv Therapeutics in the third quarter worth $116,000. State Street Corp increased its stake in shares of vTv Therapeutics by 268.7% in the second quarter. State Street Corp now owns 206,145 shares of the biotechnology company’s stock worth $155,000 after purchasing an additional 150,228 shares in the last quarter. Prudential Financial Inc. purchased a new stake in shares of vTv Therapeutics in the second quarter worth $30,000. Finally, Millennium Management LLC increased its stake in shares of vTv Therapeutics by 12.0% in the second quarter. Millennium Management LLC now owns 138,683 shares of the biotechnology company’s stock worth $104,000 after purchasing an additional 14,845 shares in the last quarter. Institutional investors own 3.36% of the company’s stock.

Analyst Ratings Changes

Separately, StockNews.com started coverage on shares of vTv Therapeutics in a research note on Tuesday, January 30th. They set a “sell” rating on the stock.

Get Our Latest Research Report on vTv Therapeutics

vTv Therapeutics Company Profile

(Get Free Report)

vTv Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company's lead drug candidate is TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis.

See Also

Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.